Wednesday, September 2, 2015

Viagra For Woman: Challenging It's Validity

Viagra For Woman

Challenging Its Validity

On August 28, 2015 Preventdisease.com published an article written by Life Choice founder and CEO Eldon Dahl. Dahl, who possesses a doctorate in natural medicine wrote an article titled Viagra For Woman.

In that article Dahl challenged the the approval of the drug  flibanserin, aka Addyi, a product that has been dubbed "Viagra for women."

In challenging the approval of this drug, Dahl center of contention focuses on the following health risks.

1) A woman's blood pressure can drop substantially (hypotension). 
2) There is also a chance that she might lose consciousness (syncope). 
3) Women are also warned not to drink alcohol while taking Addyi.

In the article Dahl takes his challenge of approval one step further and discusses in detail the flawed process in which the drug was tested as well as the invalid and inconclusive statistical data that was used to draw inferences on the drugs effectiveness. 

Finally, he concludes the article by looking at other influences in a woman's life that can lead to a lack of sexual interest; events which the drug itself will have little or no influence. 


About  


Platinum Sponsor
Life Choice is a leader in the manufacturing and supply of top quality nutraceuticals. The company only manufacturers and supplies the highest quality natural products to markets in Canada, the United States and the European Union. 

All Life Choice nutraceutcials are clinically tested, government approved and licensed. Every product in the Life Choice family is formulated under the direct supervision of Dr. Eldon Dahl
a trained naturopath and the company's founder and CEO.

All of the company's products are professionally formulated to have therapeutic and medicinal value. 

Ask your medical practitioner, naturopath physician, or health food store manger for products carrying the Life Choice label. Or better yet, please visit our website and check out our products for your self. 

No comments:

Post a Comment